Rubicon Limited announced the appointment of Andrew Baum as the CEO of the company. Andrew joined Rubicon's subsidiary ArborGen Inc. in March 2012 as president and chief executive officer. During Mr. Baum's 30-year career in the technology industry, he has served as the presidentand chief executive officer of Sembiosys Genetics Inc, taking the company from a university-based research initiative to a fully integrated, publicly traded biotechnology. His career has also included working in increasing levels of responsibility for Calgene, Inc, becoming president of the oils divisionin 1992. Following Calgene's sale to Monsanto, he served as the director of business development, sustainable development sector. Andrew has a BS in Industrial Engineering and Operations Research from the University of California, Berkeley.